Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Madeline Dahut"'
Autor:
Jeffrey Schlom, Claudia Palena, Kristen Fousek, Duane H Hamilton, Lucas A Horn, Haiyan Qin, Madeline Dahut, Shantel Angstadt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Enzalutamide, a next-generation antiandrogen agent, is approved for the treatment of metastatic castration-resistant prostate cancer (CRPC). While enzalutamide has been shown to improve time to progression and extend overall survival in me
Externí odkaz:
https://doaj.org/article/aaee34ce72d74349a73d564f6c92a17c
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/b2f9e4a7480945cf84e46b90e40a6430
Autor:
Kristen, Fousek, Lucas A, Horn, Haiyan, Qin, Madeline, Dahut, Masafumi, Iida, Dan, Yacubovich, Duane H, Hamilton, Anish, Thomas, Jeffrey, Schlom, Claudia, Palena
Publikováno v:
Journal of Thoracic Oncology. 18:350-368
SCLC is a highly aggressive tumor with a 5-year survival rate of less than 6%. A heterogeneous disease, SCLC is classified into four subtypes that include tumors with neuroendocrine and non-neuroendocrine features. Immune checkpoint blockade has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c21a8f404e2dc557baa1ad56a5650bcc
https://doi.org/10.1016/j.jtho.2022.11.008
https://doi.org/10.1016/j.jtho.2022.11.008
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7e769785e5e3567bfc95e78167a7269
https://doi.org/10.1136/jitc-2022-sitc2022.0909
https://doi.org/10.1136/jitc-2022-sitc2022.0909
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundBackground: Treatment of patients with castration-resistant prostate cancer (CRPC) includes the use of next-generation hormonal therapies such as abiraterone or enzalutamide. Although these agents extend survival, a significant proportion o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::715823d1be2b39d60fc922b8c1e2d59b
https://doaj.org/article/b2f9e4a7480945cf84e46b90e40a6430
https://doaj.org/article/b2f9e4a7480945cf84e46b90e40a6430
Publikováno v:
Cancer Research. 82:5540-5540
Androgen receptor (AR)-targeted therapies are routinely used to treat prostate cancer, including the use of next-generation hormonal therapies such as abiraterone or enzalutamide. Although these therapies are initially effective, a significant propor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::671d4be43d432362bd1615b42220c886
https://doi.org/10.1158/1538-7445.am2022-5540
https://doi.org/10.1158/1538-7445.am2022-5540
Autor:
Demarrius Young, Mark R. Gilbert, Madeline Dahut, Dorela D. Shuboni-Mulligan, Terri Armstrong
Publikováno v:
Neuro Oncol
BACKGROUND Chronotherapy is the optimally timed administration of treatment based on the circadian clock. In non-CNS cancers, circadian rhythms (CR) drive the expression of mechanisms responsible for radiation sensitivity and associated toxicity. Our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a3046107dd2dd8bf274fddce63fa97
https://europepmc.org/articles/PMC6847923/
https://europepmc.org/articles/PMC6847923/
